Who makes L.M.X.4.® cream?

L.M.X.4.® cream is developed by Ulthera, Inc.

What development phase is L.M.X.4.® cream in?

L.M.X.4.® cream is in Phase 1.

Last reviewed 2026-04-19 · How we verify

L.M.X.4.® cream

Ulthera, Inc · Phase 1 active Small molecule

At a glance

Generic name	L.M.X.4.® cream
Also known as	A lidocaine topical anesthetic cream
Sponsor	Ulthera, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

L.M.X.4.® cream CI brief — competitive landscape report
L.M.X.4.® cream updates RSS · CI watch RSS
Ulthera, Inc portfolio CI